Male urethral cancer

May be primary or secondary: primary rare; secondary commonly a/w urothelial carcinoma of the bladder

Primary urethral carcinoma usually arises secondary to chronic irritation

Urethral stricture

Frequent STI/urethritis

Presentation

haematuria

urethral bleeding

persistent urethral stricture

urethrocutaneous fistula

Histology

80% squamous cell carcinoma (a/w HPV 16)

15% transitional cell carcinoma

5% other (adenoCa, melanoma etc.)

Location

60% bulbomembranous

30% penile

10% prostatic

Generally anterior urethral tumours do better than posterior urethral tumours

Spread

Anterior urethra – superficial and deep inguinal LNs (unlike penile carcinoma palpable LNs almost always metastatic)

Posterior urethra – pelvic LNs

Staging (UICC)

- Tx Tumour cannot be assessed
- To No evidence of primary tumour
- Tis CIS
- Ta Papillary, polypoid or verucoid tumour
- T1 Tumour invades subepithelial connective tissue
- T2 Tumour invades corpus spongiosum or prostate stroma
- T3 Corpus cavernosum, vagina or bladder neck
- T4 Other adjacent structures
- Nx Nodal disease cannot be assessed
- NO No evidence of nodal disease
- N1 Metastasis to a single LN < 2cm
- N2 Metastasis to LN 2-5cm, or multiple LNs < 5cm
- N3 Metastasis to LN > 5cm
- Mx Distant mets cannot be assessed
- M0 No distant mets
- M1 Distant mets

Management

Depends on location and tumour stage:

(i) Penile urethra

Superficial (<T2) Transurethral resection

Local excision and anastomosis

Local excision and perineal urostomy

Penis tip tumours may be treated by local excision

and urethral repair

Invasive (T2+) Distal half penile urethra Partial penectomy

Prox. Half penile urethra Total penectomy 2cm margin of excision required for both Bilateral inguinal LND for palpable LNs No reported benefit for prophylactic LND

(ii) Bulbomembranous urethra

Superficial Uncommon

TUR/laser fulguration

Local excision and primary anastomosis

Invasive Radical cystoprostatectomy, pelvic LND and total

penectomy

Possible inclusion of pubic arch excision and adjacent urogenital diaphragm in continuity Limited value for radical radiation therapy – reserved for unfit patients/those who refuse

surgery

(iii) Urethral recurrence after orthotopic substitution

Urethrectomy with cuff of pouch. Excision of redundant pouch and use of chimney as ileal conduit is standard managment. Occasionally mitrofanoff/monti to neobladder but a/w high revision rate and risk of pelvic recurrence

Female urethral cancer

Primary urethral cancer only urological cancer more common in women than men

4x more common in females cf. males

Still rare however, accounting for ~ 1% femle GU malignancies

Whites > blacks

Aetiology – chronic irritation (Urethral diverticula, stricture, leukoplakia)

Presentation

Bleeding

Palpable mass

Obstructive symptoms

Acute retention

Palpable lymphadenopathy (30% - higher in more advanced disease)

Microscopy

Squamous cell carcinoma 50-70% (HPV 16)

Transitional cell carcinoma* 10-25% Adenocarcinoma** 10-25%

Anterior two-thirds of urethra drain to superficial and deep inguinal nodes: posterior third to internal and external iliac nodes

Diagnosis and staging

Cystoscopy, EUA and biopsy

MRI useful for loco-regional staging

Pelvic lymph node mets in 20%

Staging as for male urethral cancer

Treatment and prognosis

As for males, distal tumours a/w better prognosis

Distal third of urethra may be excised without compromising continence

(i) Distal tumours

Tend to be low stage

Local resection acceptable for exophytic tumours of distal third Radical urethrectomy reported with bladder closure and diversion (iliovesicostomy or appendicovesicostomy) but local recurrence rates ~20%

Radical radiotherapy a/w similar five yr-survival to surgery (55-70Gy +/-brachytherapy) – 40% 5YS

No evidence for prophylactic LN dissection – bilateral LND only recommended in palpable disease.

(ii) Proximal tumours

Tend to be higher stage

Poor 5YS with anterior exenteration alone (<20%)

^{*} transitional cell epithelium covers proximal third of urethra (distal two thirds stratified squamous epithelium)

^{**} slightly higher incidence in diverticula

Combination therapy recommended for optimal Rx

SCC = 5FU and MMC, radiation therapy and surgery

TCC = MVAC/GemCis, radiation therapy and surgery

Surgery

Wide vaginal excision+/- partial vulvectomy
Anterior exenteration and pelvic lymph node dissection
Pubic arch resection largely historical particularly if pre-operative radiotherapy considered